| Literature DB >> 25592099 |
Hakan Uçar1, Mustafa Gür, Abdürrezzak Börekçi, Arafat Yıldırım, Ahmet Oytun Baykan, Gülhan Yüksel Kalkan, Mevlüt Koç, Taner Şeker, Mehmet Coşkun, Ömer Şen, Murat Çaylı.
Abstract
OBJECTIVE: The relationship between severity of coronary artery disease (CAD) and left ventricler (LV) hypertrophy in hypertensive patients is well known. However, the association between the extent and complexity of CAD assessed with SYNTAX score (SS) and different LV geometric patterns has not been investigated. We aimed to investigate the association between SYNTAX score and different LV geometric patterns in hypertensive patients.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25592099 PMCID: PMC5336963 DOI: 10.5152/akd.2014.5747
Source DB: PubMed Journal: Anatol J Cardiol ISSN: 2149-2263 Impact factor: 1.596
Comparison of baseline, laboratory, echocardiographic, and angiographic characteristics among the groups
| Variables | NG Group | CR Group | EH Group | CH group | ANOVA P |
|---|---|---|---|---|---|
| Age, years | 60.1±9.04 | 58.46±9.6 | 61.7±9.8 | 66.10±9.8[ | <0.001 |
| Gender[ | 38 (46.0%) | 31 (45.8%) | 21 (37.5%) | 37(46.2%) | 0.852 |
| BMI, kg/m2 | 29.01±4.4 | 29.6±5.3[ | 29.3±5.2 | 28.8±5.3 | 0.911 |
| BSA, m2 | 1.87±0.17 | 1.93±0.21 | 1.83±0.17 | 1.83±0.17 | 0.020 |
| SBP, mm Hg | 145.2±15.8 | 146.7±18.5 | 149.4±18.1 | 157.0±17.1[ | <0.001 |
| DBP, mm Hg | 92.2±11.3 | 94.2±11.2 | 95.6±11.3 | 104.6±13.2[ | <0.001 |
| Heart rate, beats/minute | 76.5±12.3 | 75.2±8.5 | 76.1±13.0 | 75.4±9.7 | 0.332 |
| Diabetes[ | 36 (45.6%) | 23 (31.9%) | 21 (43.8%) | 31 (44.9%) | 0.345 |
| Hyperlipidemia[ | 36 (45.6%) | 35 (54.7%) | 17 (33.6%) | 35 (50.7%) | 0.628 |
| Smoking[ | 24 (27.6%) | 23 (35.9%) | 22 (46.3%) | 31 (44.9%) | 0.152 |
| Family history[ | 26 (32.9%) | 21 (31.8%) | 13 (23.3%) | 16 (23.2%) | 0.518 |
| Glucose, mg/dL | 140.8±8.2 | 148.3±9.3 | 149.3±13.6 | 147.4±10.3 | 0.740 |
| LDL-C, mg/dL | 117.7±23.1 | 111.2±24.8 | 109.4±20.9 | 110.7±33.1 | 0.170 |
| HDL-C, mg/dL | 44.4±6.7 | 42.4±6 | 43.7±8.5 | 44.2±7.2 | 0.463 |
| Triglyceride, mg/dL | 162.12±53 | 158.64±65 | 151.41±37 | 145.52±42 | 0.237 |
| Hemoglobin, mg/dL | 15.5±1.4 | 13.8±1.3 | 14.1.0±1.4 | 15.2±1.3 | 0.767 |
| Creatinine, mg/dL | 0.92±0.4 | 0.88±0.27 | 0.92±0.31 | 0.97±0.49 | 0.636 |
| LVEDD, cm | 5.1±4.6 | 4.3.2±3.6 | 5.1±3.9 | 4.7.2±3.6 | 0.238 |
| IVSth, cm | 0.98±.0.1[ | 1.12±0.11[ | 1.15±0.12[ | 1.23±0.1 | <0.001 |
| PWth, cm | 0.9±0.08[ | 1.08±0.1[ | 1.02±0.1[ | 1.21 ±0.09 | <0.001 |
| EF, % | 54.8±8.4[ | 55.8±7.6[ | 50.6±8.7 | 53.7±6.8 | 0.011 |
| RWth, cm | 0.39±0.03[ | 0.50±0.04[ | 0.40±0.04[ | 0.51±0.04 | <0.001 |
| LVMI, g/m2 | 96.3±17.6[ | 102.3±17.8[ | 146.1 ±32.3 | 147.6±23.9 | <0.001 |
| SYNTAX score | 9.2±7.02[ | 10.1 ±6.9[ | 12.6±7.1 | 15.2±6.8 | <0.001 |
| Previous medications | |||||
| ACE-I use, n (%) | 24 (27.6%) | 21 (31.8%) | 21 (53.8%) | 31 (44.3%) | 0.153 |
| ARB use, n (%) | 26 (32.9%) | 23 (35.9%) | 17 (43.6%) | 35 (50.7%) | 0,164 |
| Beta-blocker use, n (%) | 24 (27.6%) | 23 (35.9%) | 22 (46.3%) | 31 (44.3%) | 0.347 |
| Statin use, n (%) | 36 (45.6%) | 35 (54.7%) | 17 (33.6%) | 35 (50.7%) | 0.628 |
| OAD use, n (%) | 36 (45.6%) | 23 (31.9%) | 21 (43.8%) | 31 (44.9%) | 0.345 |
ACE-I - angiotensin-converting enzyme inhibitor; ARB - angiotensin receptor blocker; BMI - body mass index; BSA - body surface area; CH - concentric hypertrophy; CR – concentric remodeling; DBP - diastolic blood pressure; EF - ejection fraction; EH - eccentric hypertrophy; HDL-C - high-density lipoprotein cholesterol; IVSth - interventricular septal thickness; LDL-C - low-density lipoprotein cholesterol; LVEDD - left ventricle end-diastolic diameter; LVMI - left ventricle mass index; NG - normal geometry; OAD - oral antidiabetic; PWth -posterior wall thickness; RWth - relative wall thickness; SBP - systolic blood pressure
Chi-square
P<0.001 vs. NG, CR, and EH groups;
P=0.014 vs. EH group, P=0.005 vs. CH group;
P<0.001 vs. NG, CR, and EH groups;
P<0.001 vs. NG, CR, and EH groups:
P<0.001 vs. CR, EH, and CH groups;
P<0.001 vs. CH group;
P<0.001 vs. CH group;
P<0.001 vs. CR, EH, and CH groups;
P<0.001 vs. EH and CH groups;
P<0.001 vs. CH group;
P=0.007 vs. EH group;
P=0.001 vs. EH group;
P<0.001 vs. CR and CH groups;
P<0.001 vs. EH group;
P<0.001 vs. CH group;
P<0.001 vs. EH and CH groups;
P<0.001 vs. EH and CH groups;
P=0.012 vs. EH group; P<0.001 vs. CH group;
P<0.001 vs. CH group
Figure 1SYNTAX score in different left ventricle geometry patterns
CH - concentric hypertrophy; CR - concentric remodeling; EH - eccentric hypertrophy; NG - normal geometry
Bivariate and multivariate relationships of SYNTAX score
| Variables | Pearson correlation coefficient | Standardized β-regression coefficients | ||
|---|---|---|---|---|
| BMI, kg/m2 | -0.129 | 0.041 | -0.004 | 0.82 |
| Age, years | 0.150 | 0.017 | 0.163 | 0.007 |
| Diabetes, n (%) | 0.144 | 0.023 | 0.134 | 0.022 |
| HDL, mg/dL | 0.132 | 0.036 | 0.107 | 0.065 |
| Creatinine, mg/dL | 0.138 | 0.028 | 0.111 | 0.060 |
| EF, % | -0.180 | 0.004 | -0.132 | 0.034 |
| LVMI g/m2 | 0.252 | <0.001 | -0.032 | 0.710 |
| RWth, cm | 0.152 | 0.016 | 0.025 | 0.721 |
| LV Geometry | 0.331 | <0.001 | 0.316 | 0.001 |
BMI - body mass index; EF - ejection fraction; HDL - high-density lipoprotein; LV - left ventricle; LVMI - left ventricular mass index; RWth - relative wall thickness